about
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cellsMultidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia.Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.Advances in the treatment of elderly and frail patients with acute myeloid leukemia.Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia.Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling.Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia.Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.Longitudinal detection of DNMT3AR882H transcripts in patients with acute myeloid leukemia.Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological FeaturesMolecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre studyComprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter studyCytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemiaA scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemiaExtensive toxic epidermal necrolysis following brentuximab vedotin administrationRelevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemiaZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutationsFluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/MLL+ translocation in leukaemiaThe kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemiaEvaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromesMonitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrowChromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patientsFulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapyMonitoring of minimal residual disease in acute myeloid leukemiaMinimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemiaMinimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patientsHigh sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphomaMutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse
P50
Q33410699-4812B0A8-841D-4F38-B399-6FEEA42F8E73Q33758834-00920C1B-AAF1-4CF7-AD82-3DDDB6E5936EQ35104356-0D2F711F-01C1-4517-83EF-91183E354D5BQ37160624-96BFAD0B-5596-4C94-9C7D-D69BD6532B30Q38243834-32355A0E-347E-4936-8BEA-48883C367573Q38269513-CDE5D25F-974E-4726-B5D7-441C519B7B03Q39404177-66001CD3-0ACE-49E7-81A2-0C818025E810Q43440810-C9FE11E6-946B-4843-AB04-4F5F9C9E2B8DQ43558209-25B61737-EDD4-4725-8895-71FF7F045A0AQ44409582-C820675F-634B-45A1-BD74-44BD7F1D5AC3Q45191343-D8F39F7D-C3F9-4479-8E69-9910D4D19C78Q45385619-E40306C0-D772-49F6-8F8A-8079A00B4D5DQ46497211-989A3270-C817-411F-B47E-C9928DFC2491Q46748733-381AEB30-DD10-469B-8CFF-EC4079B20703Q46902467-5CAE8E8F-3155-4633-9435-7619A37DE80AQ50125166-44307761-404B-4AAA-BB20-F87D6E32C729Q53950965-CFFFB9D3-EF09-4A33-9D47-113B9124EBADQ54345184-DC4CE543-110A-45CC-92F9-CB34B021E37EQ54693168-7A6EB7C4-9EBF-4DE7-9712-57DF68C5A70AQ54704847-1AF636FB-ABE5-4880-9ADD-79EFEA193D90Q58000969-EC955F5D-3DDE-4347-B181-40054AA19672Q58001001-B27008A6-E54C-495E-8DEF-B4AAD4C03F7DQ58001030-133C638E-D44E-4AFB-B2C8-0ACD04AF6911Q58370816-37D3F0B2-1380-4796-A393-C24B1FD03CAAQ59211799-81AF53CB-580C-46A9-9025-CC5007EA1740Q59314779-C8571EB9-16C4-4A5D-A914-CB4BEABE9F6BQ60358460-A98F219B-B9D1-45F1-9654-7373003995E1Q60358588-619CCF10-4851-4F9E-8A73-77DB49AC6BB3Q73480515-27C59F42-5D20-42CB-B928-85FB30DA4C40Q79894989-9391BDE3-010B-4AD4-8B51-AB848DB98980Q79920761-36E232B1-6EEA-42F9-9A5D-294D27E69A3BQ80292588-1D8D6E1E-44C3-4281-8ADA-B25186648A4FQ80477837-714C4351-A041-437A-BF2E-BAE0F386A4B2Q81045178-AAEEF8E7-3F03-4C2C-9E0B-6E06EC4373AAQ84379802-405467C0-1961-436D-A399-A4BE8AB1AB06Q85923240-F7B4CCD4-EB05-4A18-9CC2-6CC294DC3BEBQ87106192-3AC854DA-3ECF-4874-8B8E-05E04ABD9A94Q87724723-39E1C1F1-DE98-4F25-998F-5743E8E09E95Q91778753-7CF7EE1A-163F-4FF3-9DA1-25F82EC615B9
P50
description
researcher ORCID ID = 0000-0002-3958-0669
@en
wetenschapper
@nl
name
Maria Ilaria Del Principe
@ast
Maria Ilaria Del Principe
@en
Maria Ilaria Del Principe
@es
Maria Ilaria Del Principe
@nl
type
label
Maria Ilaria Del Principe
@ast
Maria Ilaria Del Principe
@en
Maria Ilaria Del Principe
@es
Maria Ilaria Del Principe
@nl
prefLabel
Maria Ilaria Del Principe
@ast
Maria Ilaria Del Principe
@en
Maria Ilaria Del Principe
@es
Maria Ilaria Del Principe
@nl
P106
P1153
6602475198
P21
P31
P496
0000-0002-3958-0669